Cabaletta Bio (CABA) Competitors $2.75 +0.04 (+1.48%) (As of 12/17/2024 05:56 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CABA vs. HUMA, MREO, PRTC, CRMD, ANAB, XERS, RNAC, MGTX, ABVX, and GLUEShould you be buying Cabaletta Bio stock or one of its competitors? The main competitors of Cabaletta Bio include Humacyte (HUMA), Mereo BioPharma Group (MREO), PureTech Health (PRTC), CorMedix (CRMD), AnaptysBio (ANAB), Xeris Biopharma (XERS), Cartesian Therapeutics (RNAC), MeiraGTx (MGTX), ABIVAX Société Anonyme (ABVX), and Monte Rosa Therapeutics (GLUE). These companies are all part of the "pharmaceutical products" industry. Cabaletta Bio vs. Humacyte Mereo BioPharma Group PureTech Health CorMedix AnaptysBio Xeris Biopharma Cartesian Therapeutics MeiraGTx ABIVAX Société Anonyme Monte Rosa Therapeutics Cabaletta Bio (NASDAQ:CABA) and Humacyte (NASDAQ:HUMA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, valuation, analyst recommendations, media sentiment, dividends, profitability and risk. Is CABA or HUMA more profitable? Cabaletta Bio's return on equity of -50.10% beat Humacyte's return on equity.Company Net Margins Return on Equity Return on Assets Cabaletta BioN/A -50.10% -45.49% Humacyte N/A -942.81%-93.82% Does the media favor CABA or HUMA? In the previous week, Humacyte had 29 more articles in the media than Cabaletta Bio. MarketBeat recorded 31 mentions for Humacyte and 2 mentions for Cabaletta Bio. Cabaletta Bio's average media sentiment score of 0.39 beat Humacyte's score of 0.09 indicating that Cabaletta Bio is being referred to more favorably in the media. Company Overall Sentiment Cabaletta Bio Neutral Humacyte Neutral Does the MarketBeat Community favor CABA or HUMA? Cabaletta Bio received 59 more outperform votes than Humacyte when rated by MarketBeat users. Likewise, 72.95% of users gave Cabaletta Bio an outperform vote while only 63.83% of users gave Humacyte an outperform vote. CompanyUnderperformOutperformCabaletta BioOutperform Votes8972.95% Underperform Votes3327.05% HumacyteOutperform Votes3063.83% Underperform Votes1736.17% Do institutionals & insiders believe in CABA or HUMA? 44.7% of Humacyte shares are held by institutional investors. 9.9% of Cabaletta Bio shares are held by insiders. Comparatively, 11.2% of Humacyte shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more risk & volatility, CABA or HUMA? Cabaletta Bio has a beta of 2.37, meaning that its share price is 137% more volatile than the S&P 500. Comparatively, Humacyte has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500. Do analysts rate CABA or HUMA? Cabaletta Bio currently has a consensus target price of $26.25, indicating a potential upside of 854.55%. Humacyte has a consensus target price of $13.00, indicating a potential upside of 242.11%. Given Cabaletta Bio's stronger consensus rating and higher possible upside, equities analysts clearly believe Cabaletta Bio is more favorable than Humacyte.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cabaletta Bio 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10Humacyte 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has better valuation & earnings, CABA or HUMA? Cabaletta Bio has higher earnings, but lower revenue than Humacyte. Humacyte is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCabaletta BioN/AN/A-$67.68M-$2.15-1.28Humacyte$1.57M304.63-$110.78M-$1.34-2.84 SummaryCabaletta Bio beats Humacyte on 11 of the 16 factors compared between the two stocks. Ad Crypto 101 MediaAI Crypto Tool Could Send One Coin SOARING…The #1 AI Coin to Buy Rapid growth predicted for little-known AI crypto projectDiscover our #1 crypto pick before it's too late. Get Cabaletta Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for CABA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CABA vs. The Competition Export to ExcelMetricCabaletta BioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$134.41M$2.98B$5.19B$9.32BDividend YieldN/A1.85%4.78%4.06%P/E Ratio-1.2846.24128.2217.54Price / SalesN/A420.891,259.00139.66Price / CashN/A182.1341.2237.95Price / Book0.503.924.884.92Net Income-$67.68M-$42.03M$119.69M$225.78M7 Day Performance-10.28%-3.37%16.64%-1.56%1 Month Performance1.85%7.95%16.32%6.68%1 Year Performance-86.82%21.00%35.37%22.48% Cabaletta Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CABACabaletta Bio2.888 of 5 stars$2.75+1.5%$26.25+854.5%-86.6%$134.41MN/A-1.2850HUMAHumacyte3.5534 of 5 stars$4.22+2.9%$13.00+208.1%+22.8%$531.13M$1.57M-3.06150Short Interest ↑MREOMereo BioPharma Group2.4674 of 5 stars$3.41-8.8%$7.40+117.0%+65.9%$529.05M$1M0.0040Positive NewsGap DownPRTCPureTech Health1.8946 of 5 stars$22.02+8.2%$45.00+104.4%+24.4%$527.20M$3.33M0.00100News CoverageGap DownHigh Trading VolumeCRMDCorMedix2.3198 of 5 stars$8.48+1.2%$15.20+79.2%+158.0%$514.54M$12.26M-10.3530Positive NewsANABAnaptysBio2.3992 of 5 stars$16.67+6.9%$45.09+170.5%-16.9%$507.27M$17.16M-2.80100Short Interest ↑Analyst RevisionNews CoverageXERSXeris Biopharma3.907 of 5 stars$3.40+3.7%$4.87+43.1%+68.8%$506.87M$163.91M-7.29290Positive NewsRNACCartesian Therapeutics2.644 of 5 stars$19.50+4.3%$43.00+120.5%-18.4%$495.69M$26M-0.3537Positive NewsMGTXMeiraGTx4.2578 of 5 stars$6.30+2.9%$23.50+273.0%+42.2%$492.36M$13.93M-5.06300ABVXABIVAX Société Anonyme2.2713 of 5 stars$7.71+8.4%$38.67+401.5%-24.4%$488.41MN/A0.0061Positive NewsGap UpGLUEMonte Rosa Therapeutics2.4508 of 5 stars$7.88+4.2%$16.00+103.0%+53.4%$484.12M$14.98M-4.1390 Related Companies and Tools Related Companies HUMA Competitors MREO Competitors PRTC Competitors CRMD Competitors ANAB Competitors XERS Competitors RNAC Competitors MGTX Competitors ABVX Competitors GLUE Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CABA) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cabaletta Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cabaletta Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
